Table 2 Comparison of data from baseline and testing phase of 52 patients with NB who underwent SNM treatment.
Parameters | Baseline | Testing phase | t/Z | P |
|---|---|---|---|---|
Voiding times | 12.1 ± 4.6 | 8.3 ± 2.0 | 4.543 | < 0.001 |
Average voiding volume (mL) | 108.6 ± 65.7 | 155.2 ± 95.9 | − 4.259 | < 0.001 |
Daily catheterization frequency | 7.8 ± 2.8 | 6.7 ± 2.2 | 2.918 | 0.006 |
Daily catheterization volume (mL) | 281.8 ± 134.9 | 221.8 ± 148.1 | 4.345 | < 0.001 |
Functional bladder capacity (mL) | 122.3 ± 78.7 | 187.9 ± 119.0 | − 4.386 | < 0.001 |
Quality of life score | 8.7 ± 1.7 | 5.1 ± 2.9 | 8.924 | < 0.001 |
OABSS score | 4.0 [3.0, 8.0] | 2.0 [1.0, 3.0] | − 4.452 | < 0.001 |
Bowel dysfunction score | 10.2 ± 5.5 | 5.0 ± 3.9 | 6.345 | < 0.001 |
Maximum urine flow rate (mL/s) | 6.7 ± 4.1 | 9.8 ± 6.1 | − 5.849 | < 0.001 |
Postvoid residual volumes (mL) | 301.3 ± 127.1 | 232.4 ± 119.9 | 3.521 | 0.001 |
Maximum detrusor pressure before voiding (cmH2O) | 31.7 ± 13.3 | 21.7 ± 11.2 | 3.759 | 0.001 |
Bladder compliance (mL/cmH2O) | 9.0 ± 5.9 | 16.9 ± 11.8 | − 3.683 | 0.001 |
Maximum cystometric capacity (mL) | 227.9 ± 71.2 | 285.2 ± 73.6 | − 4.176 | < 0.001 |
